Wegovy for Obesity: How It Compares in 2025
Wegovy is an FDA-approved GLP-1 receptor agonist specifically designed for chronic weight management. As of 2025, it remains one of the most prescribed medications for obesity due to its strong clinical outcomes and weekly injection convenience.
🔍 Key Facts About Wegovy
- Approved for adults with BMI ≥30 or ≥27 with weight-related conditions
- Delivers significant weight loss over 68 weeks of use
- Administered weekly via subcutaneous injection
Compared to other GLP-1 options like Ozempic and Tirzepatide, Wegovy focuses more on weight reduction rather than blood sugar management.
For full comparison of GLP-1 treatments, visit our guide: Top GLP-1 Drugs for Diabetes and Obesity in 2025.
💡 Pro Tip: Patients switching from Ozempic to Wegovy should monitor GI symptoms and titrate dosage under medical supervision.